CK Life Sciences Presenting Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-targeting PRAME and PD-L1, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
<p>HONG KONG SAR - <a href="https://www.media-outreach.com/">Media OutReach</a> - 1 November 2023 - CK Life Sciences Int'l., (Holdings) Inc. is presenting preclinical data for its investigational dual-antigen cancer vaccines, co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed death-ligand 1), on November 4<b> </b>at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California, USA.</p>